G. Freeman
Immunology · Nature · 2000–2020
A researcher in the Science corpus: 45 papers; trusts 19 researchers and is trusted by 39 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 559 citations into it; #44 of 2,160 by trust here, #9 by citations
- Oncology — 460 citations into it; #28 of 1,698 by trust here, #16 by citations
Whom G. Freeman trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts G. Freeman overall
- Arlene H. Sharpe
- Lieping Chen
- D. Pardoll
- E. Wherry
- James L. Riley
- B. Fife
- Padmanee Sharma
- W. Zou
- S. Topalian
- A. Schietinger
Papers from G. Freeman's perspective
Ordered by how strongly the researchers G. Freeman trusts endorse each paper. Same corpus, a different order for every researcher.
- Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade (Proceedings of the National Academy of Sciences of the United States of America)
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
- Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (Nature Medicine)
- Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. (Immunity)
- The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection (Nature Immunology)
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma (Nature Medicine)
- Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. (Cancer Research)
- Foxp3 programs the development and function of CD4+CD25+ regulatory T cells (Nature Immunology)
- Regulatory T cell lineage specification by the forkhead transcription factor foxp3. (Immunity)
Their papers
- Fusobacterium nucleatum and T-cells in Colorectal Carcinoma (2015) — 618 citations
- PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation (2015) — 1,091 citations
- Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis (2015) — 976 citations
- Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance (2003) — 677 citations
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma (2020) — 821 citations
- Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 (2018) — 803 citations
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response (2018) — 4,258 citations
- LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade (2018) — 596 citations
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity (2017) — 757 citations
- Rescue of exhausted CD8 T cells by PD-1 targeted therapies is CD28-dependent (2017) — 903 citations
- Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance (2017) — 762 citations
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints (2016) — 1,425 citations
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. (2016) — 938 citations
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy (2016) — 1,792 citations
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. (2016) — 701 citations
- Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy (2016) — 893 citations
- Coinhibitory Pathways in Immunotherapy for Cancer. (2016) — 862 citations
- Combination cancer immunotherapy and new immunomodulatory targets (2015) — 1,207 citations
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (2014) — 3,318 citations
- Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens (2014) — 1,894 citations